Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17643116 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL20983468 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL17643270 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL17643452 | 0.91 | GRIN1 (0.84) | GRIN1GRIN2B | |
| SCHEMBL20086386 | 0.90 | GRIN1 (0.82) | GRIN1GRIN2B | |
| SCHEMBL20086338 | 0.90 | GRIN1 (0.82) | GRIN1GRIN2B | |
| SCHEMBL24136375 | 0.87 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL20983486 | 0.87 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL17643277 | 0.87 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL17643120 | 0.87 | GRIN1 (1.00) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145909-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B | NOVARTIS AG (CH) | 2024-11-19 | — | — | US | disclosed |
| EP-4282412-A2 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3974420-B1 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | NOVARTIS AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-20220274925-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | US | disclosed |
| EP-3974420-A1 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Cadent Therapeutics, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274925-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN1 5/4885GRIN2B 4/4885 |
| US-12145909-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN1 5/4885GRIN2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.